Files and links (2)
Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis - from pharmacology to pre-clinical and clinical therapeutics876.21 kB
Published VersionCC BY V4.0, Open Access
Journal article
Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics
Theranostics, Vol.11(9), pp.4502-4515
2021
PMID: 33754074
Abstract
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are new oral drugs for the therapy of patients with type 2 diabetes mellitus (T2DM). Research in the past decade has shown that drugs of the SGLT2i class, such as empagliflozin, canagliflozin, and dapagliflozin, have pleiotropic effects in preventing cardiovascular diseases beyond their favorable impact on hyperglycemia. Of clinical relevance, recent landmark cardiovascular outcome trials have demonstrated that SGLT2i reduce major adverse cardiovascular events, hospitalization for heart failure, and cardiovascular death in T2DM patients with/without cardiovascular diseases (including atherosclerotic cardiovascular diseases and various types of heart failure). The major pharmacological action of SGLT2i is through inhibiting glucose re-absorption in the kidney and thus promoting glucose excretion. Studies in experimental models of atherosclerosis have shown that SGLT2i ameliorate the progression of atherosclerosis by mechanisms including inhibition of vascular inflammation, reduction in oxidative stress, reversing endothelial dysfunction, reducing foam cell formation and preventing platelet activation. Here, we summarize the anti-atherosclerotic actions and mechanisms of action of SGLT2i, with an aim to emphasize the clinical utility of this class of agents in preventing the insidious cardiovascular complications accompanying diabetes.
Details
- Title
- Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics
- Authors
- Zhenghong Liu (Author) - University of Science and Technology of ChinaXiaoxuan Ma (Author) - University of Science and Technology of ChinaIqra Ilyas (Author) - University of Science and Technology of ChinaXueying Zheng (Author) - University of Science and Technology of ChinaSihui Luo (Author) - University of Science and Technology ChittagongPeter J Little (Author) - University of the Sunshine Coast, Queensland, School of Health and Behavioural Sciences - LegacyDanielle Kamato (Author) - The University of QueenslandAmirhossein Sahebkar (Author) - Mashhad University of Medical SciencesWeiming Wu (Author) - Nanjing University of Chinese MedicineJianping Weng (Author) - University of Science and Technology of ChinaSuowen Xu (Author) - University of Science and Technology of China
- Publication details
- Theranostics, Vol.11(9), pp.4502-4515
- Publisher
- Ivyspring International Publisher
- Date published
- 2021
- DOI
- 10.7150/thno.54498
- ISSN
- 1838-7640
- PMID
- 33754074
- Copyright note
- © The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/).
- Organisation Unit
- School of Health; University of the Sunshine Coast, Queensland; School of Health and Behavioural Sciences - Legacy
- Language
- English
- Record Identifier
- 99522508602621
- Output Type
- Journal article
Metrics
6 File views/ downloads
30 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Domestic collaboration
- International collaboration
- Web Of Science research areas
- Medicine, Research & Experimental
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites